| EISAI |
EISAI |
92%
|
In addition, Eisai is required to pay to the Company certain tiered royalties at rates in the low- to high-teens on aggregate annual net sales of licensed products during the applicable royalty term,… |
| SAGARD-HOLDINGS |
SAGARD-HOLDINGS |
85%
|
ng supply, build out of additional commercial infrastructure, substantial investment and significant marketing efforts, before we generate any revenue from product sales. We are not permitted to mark… |
| AZN |
AstraZeneca PLC |
72%
|
t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from AZN grap… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we ob… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from BMYM… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we o… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF |
Sanofi |
72%
|
t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a long-term supply agreement. We are currently… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we … |
| ANHEART-THERAPEUTICS-INC |
ANHEART-THERAPEUTICS-INC |
62%
|
our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Further, we, the FDA or comparable foreign regulatory authorities, an… |
| DAIICHI-SANKYO-COMPANY-LIMITED |
DAIICHI-SANKYO-COMPANY-LIMITED |
62%
|
our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Further, we, the FDA or comparable foreign regulatory authorities, an… |
| DAIICHI-SANKYO-COMPANY-LTD |
DAIICHI-SANKYO-COMPANY-LTD |
62%
|
d was determined based on other inputs that are observable, and thus categorized as Level 2 in the fair value hierarchy. The fair value of the liability related to the sale of future royalties is bas… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ired import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requireme… |
| EISAI-CO-LTD |
EISAI-CO-LTD |
62%
|
ple development stage drug candidates globally or in specific territories. The development milestone payments are recognized when the achievement of the associated milestone becomes probable and esti… |
| HANGZHOU-CO-LTD |
HANGZHOU-CO-LTD |
62%
|
ired import or export authorization for our products, when applicable, could harm our international or domestic sales and adversely affect our revenue. Compliance with applicable regulatory requireme… |
| INNOVENT-BIOLOGICS-CO-LTD |
INNOVENT-BIOLOGICS-CO-LTD |
62%
|
ple development stage drug candidates globally or in specific territories. The development milestone payments are recognized when the achievement of the associated milestone becomes probable and esti… |
| NIPPON-KAYAKU-CO-LTD |
NIPPON-KAYAKU-CO-LTD |
62%
|
ple development stage drug candidates globally or in specific territories. The development milestone payments are recognized when the achievement of the associated milestone becomes probable and esti… |
| PANACEA-ACQUISITION-CORP |
PANACEA-ACQUISITION-CORP |
62%
|
interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve a… |
